KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Inventory (2018 - 2025)

Historic Inventory for Alnylam Pharmaceuticals (ALNY) over the last 8 years, with Q4 2025 value amounting to $82.7 million.

  • Alnylam Pharmaceuticals' Inventory rose 536.24% to $82.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $82.7 million, marking a year-over-year increase of 536.24%. This contributed to the annual value of $82.7 million for FY2025, which is 536.24% up from last year.
  • As of Q4 2025, Alnylam Pharmaceuticals' Inventory stood at $82.7 million, which was up 536.24% from $75.4 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Inventory high stood at $131.9 million for Q1 2023, and its period low was $65.6 million during Q1 2025.
  • For the 5-year period, Alnylam Pharmaceuticals' Inventory averaged around $90.0 million, with its median value being $85.4 million (2021).
  • Within the past 5 years, the most significant YoY rise in Alnylam Pharmaceuticals' Inventory was 6796.45% (2023), while the steepest drop was 3087.42% (2023).
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Inventory stood at $86.4 million in 2021, then soared by 49.33% to $129.0 million in 2022, then tumbled by 30.87% to $89.1 million in 2023, then decreased by 11.93% to $78.5 million in 2024, then grew by 5.36% to $82.7 million in 2025.
  • Its last three reported values are $82.7 million in Q4 2025, $75.4 million for Q3 2025, and $71.7 million during Q2 2025.